(S)-[(3aS,5S,6R,6aS)-6-(tert-butyl-dimethyl-silanyloxy)-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-5-yl]-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-methanol | 1018898-78-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-[(3aS,5S,6R,6aS)-6-(tert-butyl-dimethyl-silanyloxy)-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-5-yl]-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-methanol
• 英文别名: (S)-[(3aS,5S,6R,6aS)-6-[tert-butyl(dimethyl)silyl]oxy-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl]-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]methanol
• CAS: 1018898-78-6
• 化学式: C₂₉H₄₁ClO₆Si
• 分子量: 549.179
• InChiKey: IRIDEQXVUKKTBV-ZEEZOPKCSA-N

物化性质

• 沸点：
  586.4±50.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.63
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  66.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (S)-[(3aS,5S,6R,6aS)-6-(tert-butyl-dimethyl-silanyloxy)-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-5-yl]-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-methanol 在 乙酰氯 作用下， 反应 2.25h， 生成 (2S,3R,4R,5S)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-ethoxy-tetrahydro-pyran-3,4,5-triol 、 (2S,3R,4R,5S)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-ethoxy-tetrahydro-pyran-3,4,5-triol
  参考文献：
  名称：

  WO2008/42688

  摘要：

  公开号：
• 作为产物：
  描述：

  (3aS,5R,6R,6aS)-6-((tert-butyldimethylsilyl)oxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxole-5-carbaldehyde 在 正丁基锂 作用下， 以 四氢呋喃 、 hexanes 为溶剂， 反应 2.0h， 以30%的产率得到(S)-[(3aS,5S,6R,6aS)-6-(tert-butyl-dimethyl-silanyloxy)-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-5-yl]-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-methanol
  参考文献：
  名称：

  WO2008/42688

  摘要：

  公开号：

文献信息

• Novel <scp>l</scp>-Xylose Derivatives as Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes
  作者：Nicole C. Goodwin、Ross Mabon、Bryce A. Harrison、Melanie K. Shadoan、Zheng Y. Almstead、Yiling Xie、Jason Healy、Lindsey M. Buhring、Christopher M. DaCosta、Jennifer Bardenhagen、Faika Mseeh、Qingyun Liu、Amr Nouraldeen、Alan G. E. Wilson、S. David Kimball、David R. Powell、David B. Rawlins

  DOI：10.1021/jm900951n

  日期：2009.10.22

  The prevalence of diabetes throughout the world continues to increase and has become a major health issue. Recently there have been several reports of inhibitors directed toward the sodium-dependent glucose cotransporter 2 (SGLT2) as a method of maintaining glucose homeostasis in diabetic patients. Herein we report the discovery of the novel O-xyloside 7c that inhibits SGLT2 in vitro and urinary glucose

  全世界的糖尿病患病率持续上升，已经成为一个主要的健康问题。最近，有几篇针对钠依赖性葡萄糖共转运蛋白2（SGLT2）的抑制剂的报道，作为维持糖尿病患者葡萄糖体内稳态的一种方法。在本文中，我们报道了在体外抑制SGLT2和在体内尿葡萄糖重吸收的新型O-木糖苷7c的发现。
• Sulfanyl-tetrahydropyran-based compounds and methods of their use
  申请人：Harrison Bryce Alden

  公开号：US08476413B2

  公开（公告）日：2013-07-02

  Sulfanyl-tetrahydropyran-based compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment of diseases and disorders such as diabetes and obesity are disclosed.

  本发明公开了基于硫代基-四氢吡喃的化合物，包括它们的药物组成物，以及它们用于治疗疾病和疾病如糖尿病和肥胖症的方法。
• SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE
  申请人：HARRISON Bryce Alden

  公开号：US20140135277A1

  公开（公告）日：2014-05-15

  Sulfanyl-tetrahydropyran-based compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment of diseases and disorders such as diabetes and obesity are disclosed.

  本发明揭示了基于Sulfanyl-tetrahydropyran的化合物，包括它们的药物组合物，并且揭示了它们用于治疗糖尿病和肥胖症等疾病和障碍的方法。
• Sodium glucose co-transporter inhibitors and methods of their use
  申请人：Harrison Bryce Alden

  公开号：US09365602B2

  公开（公告）日：2016-06-14

  Sulfanyl-tetrahydropyran-based compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment of diseases and disorders such as diabetes and obesity are disclosed.

  本发明揭示了基于硫代基四氢吡喃的化合物，包括它们的制药组合物以及它们在治疗疾病和疾患，如糖尿病和肥胖症方面的使用方法。
• SULFANYL-TETRAHYDROPYRAN-BASED COMPOUNDS AND METHODS OF THEIR USE
  申请人：Harrison Bryce Alden

  公开号：US20100311673A1

  公开（公告）日：2010-12-09

  Sulfanyl-tetrahydropyran-based compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment of diseases and disorders such as diabetes and obesity are disclosed.

  本发明涉及基于硫代基四氢吡喃的化合物，包括它们的制药组合物以及使用它们治疗糖尿病和肥胖等疾病和疾病的方法。